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Recent studies have suggested that the plasma membrane contains cholesterol-enriched microdomains known as lipid rafts. HIV-1 Gag binds
raft-rich regions of the plasma membrane, and cholesterol depletion impairs HIV-1 particle production. In this study, we sought to define the block
imposed by cholesterol depletion. We observed that membrane binding and higher-order multimerization of Gag were markedly reduced upon
cholesterol depletion. Fusing to Gag a highly efficient, heterologous membrane-binding sequence reversed the defects in Gag–membrane binding
and multimerization caused by cholesterol depletion, indicating that the impact of reducing the membrane cholesterol content on Gag–membrane
binding and multimerization can be circumvented by increasing the affinity of Gag for membrane. Virus release efficiency of this Gag derivative
was minimally affected by cholesterol depletion. Altogether, these results are consistent with the hypothesis that cholesterol-enriched membrane
microdomains promote HIV-1 particle production by facilitating both Gag–membrane binding and Gag multimerization.
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Human immunodeficiency virus type 1 (HIV-1), like many
other retroviruses, assembles into virus particles in association
with cellular membrane (Freed, 1998; Swanstrom and Wills,
1997). Retrovirus particle production, driven by the viral Gag
protein, is a multi-step process that includes: 1) Gag transport to
the site of virus assembly, 2) Gag binding to a lipid bilayer, 3) Gag
multimerization, and 4) budding and pinching-off of nascent virus
particles from the host cell membrane. In the case of HIV-1,
depending on the cell type in which Gag is expressed, virus
particle formation takes place either at the plasmamembrane (PM)
or in late endosomes/multivesicular bodies (MVBs) (Grigorov et
al., 2006; Nydegger et al., 2003; Ono and Freed, 2004; Pelchen-
Matthews et al., 2003; Perlman and Resh, 2006; Raposo et al.,
2002; Rudner et al., 2005; Sherer et al., 2003). HIV-1 Gag is
synthesized as a precursor polyprotein, Pr55Gag, which consists of⁎ Corresponding author. Department of Microbiology and Immunology,
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doi:10.1016/j.virol.2006.10.011four major structural domains: matrix (MA), capsid (CA),
nucleocapsid (NC), and p6 and two spacer peptides, SP1 and
SP2. Upon virus particle release, these domains and spacer
peptides are cleaved by the viral protease (PR) to generate
p17MA, p24CA, p7NC, p6, SP1, and SP2, respectively.
The MA domain contains determinants for Gag binding to
the lipid bilayer and Gag targeting to the PM. The former
function is mediated in part by the N-terminal myristate moiety
(Freed, 1998; Swanstrom and Wills, 1997). The myristyl chain
is thought to adopt either of two conformational states: exposed
or sequestered within the globular head of MA. According to
the myristyl switch model (Zhou and Resh, 1996), Gag binds
lipid bilayers efficiently when the myristate is exposed but
poorly when it is sequestered. Consistent with this model,
amino acid substitutions near the N-terminus of MA or
deletions in the MA globular head modulate Gag–membrane
binding (Ono and Freed, 1999; Paillart and Gottlinger, 1999;
Perez-Caballero et al., 2004). In the WT context, Gag multi-
merization likely promotes the exposure of the myristate moiety
(Hermida-Matsumoto and Resh, 1999; Perez-Caballero et al.,
2004; Sandefur et al., 2000; Sandefur et al., 1998; Spearman et
al., 1997; Tang et al., 2004; Zhou and Resh, 1996). In addition
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and a highly basic region of MA (located between MA amino
acids 17 and 32) are implicated in Gag–membrane binding
(Zhou et al., 1994). This highly basic sequence is also a
determinant of Gag localization to the PM; amino acid
substitutions in this region cause retargeting of Gag to the late
endosome/MVB even in cell types in which WT Gag is targeted
to the PM (Freed et al., 1994; Hermida-Matsumoto and Resh,
2000; Ono and Freed, 2004; Ono et al., 2000b; Yuan et al.,
1993). Gag multimerization is mediated by a region spanning
the C-terminal domain of CA, SP1, and the N-terminal portion
of NC. The CA C-terminal domain likely mediates Gag
dimerization while NC promotes higher-order Gag multi-
merization by binding to RNA molecules that may serve as
assembly scaffolds (Adamson and Jones, 2004). p6 facilitates
pinching-off of nascent virus particles from the PM by
recruiting cellular machinery that usually functions in the
budding of intraluminal vesicles into late endosomes (Demirov
and Freed, 2004; Morita and Sundquist, 2004).
It is now well established that the PM is not a homogenous
lipid bilayer but rather is composed of various microdomains
containing unique sets of proteins and lipids. Among these,
cholesterol- and saturated-lipid-enriched microdomains known
as lipid rafts have been the subject of much interest and debate
across several disciplines of biology. Cholesterol likely
promotes formation of a liquid-ordered structure through
interactions with saturated acyl chains in lipid rafts (Brown
and London, 2000; Simons and Toomre, 2000; Simons and Vaz,
2004). Lipid rafts can be isolated biochemically based on their
insolubility in a number of nonionic detergents (e.g., Triton X-
100) at low temperature (Brown and Rose, 1992). Although
detergent-resistant membrane (DRM) is unlikely to represent
intact rafts present in undisrupted cells (Edidin, 2003;
Heerklotz, 2002; Munro, 2003), and a population of raft-
associated molecules may be lost from DRM during isolation
procedures (Harder et al., 1998), DRM binding can serve as a
useful criterion for raft association. To corroborate results
obtained by such biochemical methods, molecules of interest
are often examined for their copatching or colocalization with
raft marker proteins and lipids. As cholesterol plays an
important role in maintaining lipid raft integrity (Brown and
London, 2000; Simons and Toomre, 2000), the functional
significance of rafts in cellular processes has been assessed by
using cholesterol depletion approaches. Based on results
obtained by a combination of biochemical, microscopic, and
pharmacological methods, rafts have been implicated in a large
number of cellular functions such as signal transduction and
protein trafficking (Brown and London, 2000; Simons and
Toomre, 2000). In such cellular pathways, rafts are postulated to
serve as concentration platforms that facilitate interactions
among raft-associated molecules. Alternatively or in addition,
rafts may function as transport vehicles that allow specific
proteins and lipids to target a specific subcellular location.
Over the past several years, lipid rafts have been implicated
in the replication of an increasing number of viruses (Ono and
Freed, 2005). In particular, members of several families of
enveloped viruses have been reported to utilize rafts during theassembly and release phase of their replication cycles (for
reviews, see Briggs et al., 2003; Ono and Freed, 2005;
Suomalainen, 2002). In these reports, viral glycoproteins and/
or inner structural proteins of the orthomyxoviruses, paramyx-
oviruses, filoviruses, and retroviruses were observed to interact
with rafts based on either their association with DRM, their
colocalization with raft markers, or both. Genetic studies of
viral mutants that are defective in DRM association suggested
correlations between the extent of DRM association of these
viral structural proteins and the efficiency of virus particle
production (e.g., Panchal et al., 2003; Takeda et al., 2003).
Because mutations in viral structural proteins often have
pleiotropic effects on virus assembly and release, however,
the physiological significance of the reported interactions
between viral proteins and lipid rafts remains to be determined.
Multiple lines of evidence suggest that lipid rafts play a role in
HIV-1 assembly and release. 1) The virion lipid bilayer is enriched
in cholesterol and sphingolipids relative to the host cell plasma
membrane (Aloia et al., 1993; Brugger et al., 2006). 2) The Gag
proteins of HIV-1 and other retroviruses have been shown to
associate with rafts in DRM binding assays (Ding et al., 2003;
Feng et al., 2003; Halwani et al., 2003; Holm et al., 2003;
Lindwasser and Resh, 2001; Nguyen andHildreth, 2000; Ono and
Freed, 2001; Pickl et al., 2001; Yang and Ratner, 2002). Although
the association of Gag with DRM has been the subject of debate
(Ding et al., 2003; Holm et al., 2003), technical differences
between studies likely explain the differences in interpretation
(Ono et al., 2005). 3) Gag proteins colocalize or copatch with raft
markers (Holm et al., 2003; Nguyen and Hildreth, 2000; Ono and
Freed, 2005). 4) Virus particle production is inhibited by
cholesterol depletion (Ono and Freed, 2001; Pickl et al., 2001)
and by substitution of myristate with unsaturated analogs, which
inhibits Gag association with liquid-ordered microdomains
(Lindwasser and Resh, 2002). Altogether, these results suggest
that lipid rafts play an important role in HIV-1 particle production.
In this report, we sought to define the role(s) of cholesterol-
enriched membrane microdomains in HIV-1 assembly and
release. To this end,we examined the impact of cellular cholesterol
depletion on each step of the virus particle production process. The
results demonstrate that PM cholesterol is important for efficient
binding of Gag to membrane and for higher-order Gag multi-
merization, but is not required for proper subcellular Gag
targeting. We suggest that the primary function of rafts in HIV-1
assembly is to provide a platform for stable binding of Gag to
membrane and for efficient Gag multimerization.
Results
Cholesterol depletion does not affect targeting of Gag to the
PM
It was reported that disruption of HIV-1 Gag–raft association
with unsaturated myristate analogs caused a mislocalization of
Gag to intracellular compartments (Lindwasser and Resh, 2002).
To examine whether Gag targeting to the PM is affected by
cholesterol depletion, HeLa cells were transfected with WT
pNL4-3, treated with either methyl-β-cyclodextrin (MβCD),
Fig. 1. Depletion of cellular cholesterol disrupts membrane binding and higher-order multimerization of HIV-1 Gag. HeLa cells were either infected with VSV-G-
pseudotyped virus transducing NL4-3/PR− or transfected with an expression plasmid encoding FynGFP. Cells were pooled, and cellular cholesterol was depleted using
10 mMMβCD (MβCD) or 2 μM simvastatin (simva.) as described in Materials and methods. Cells were pulse-labeled with [35S]Met/Cys for 5 min and were chased
for 15 min. PNSs of cell homogenates were fractionated by membrane flotation. Fractions were treated with RIPA buffer and membrane (M) and non-membrane (NM)
fractions were pooled. Labeled Pr55Gag and FynGFP in each pooled fraction were recovered by immunoprecipitation using HIV-Ig and rabbit anti-GFP antibody,
respectively. Prior to immunoprecipitation with HIV-Ig, the fractions were denatured to expose epitopes masked by Gag multimerization. Immunoprecipitated material
was analyzed by SDS-PAGE followed by autoradiography (A) and signal intensity of Pr55Gag (B) and FynGFP (C) was quantified by phosphorimager analysis. Data
from six independent experiments are shown as means±standard error of the means. p values were determined by the Student's t-test (***p<0.001, **p<0.01). In
(D), labeled Pr55Gag in pooled membrane fractions was recovered by immunoprecipitation either without or with prior denaturation. Signal intensity was quantified by
phosphorimager analysis and epitope exposure of Gag in non-denatured samples was calculated relative to denatured samples. Data from six independent experiments
are shown as means±standard error of the means. p values were determined by the Student's t-test (**p<0.005, *p<0.05).
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inhibits cholesterol biosynthesis, and immunostained with a
mixture of anti-p17MA and anti-p24CA antibodies. In choles-
terol-depleted cultures, Gag still localized to the PM and not to
intracellular compartments, although a number of cells showed
an increase in hazy cytoplasmic localization relative to cell-
surface punctate signal (data not shown). These results indicate
that cholesterol depletion does not cause amistargeting of Gag to
intracellular compartments, but suggest that cholesterol removal
may reduce binding of Gag to membrane.
Depletion of cellular membrane cholesterol reduces
Gag–membrane binding
We have shown previously that Gag binding to total cellular
membrane precedes DRM association (Ono and Freed, 2001).
These data suggest that initial Gag–membrane binding does not
require the presence of intact lipid rafts. Nonetheless, it is possiblethat Gag interaction with the lipid bilayer may be stabilized or
enhanced by the presence of lipid rafts in the membrane. To
address this possibility, we sought to determine whether
cholesterol depletion from virus-producing cells affects the
binding of Gag to membrane. HeLa cells were infected with
vesicular stomatitis virus G (VSV-G)-pseudotyped virus expres-
sing NL4-3/PR−, which lacks a functional viral protease (PR).
Infected cells were either left untreated or depleted of cholesterol
with MβCD or simvastatin. In the conditions used in these
experiments, we typically observe an approximately threefold
reduction in plasma membrane cholesterol (Ono and Freed, 2001).
To monitor global effects on membrane that might be induced by
cholesterol depletion, HeLa cells expressing FynGFP were mixed
with Gag-expressing cells prior to cholesterol depletion. FynGFP
contains the myristylated and palmitoylated Fyn N-terminus
linked to GFP (van't Hof and Resh, 1997). Cells were pulse-
labeled for 5 min with [35S]Met/Cys and chased for 15 min. Post-
nuclear supernatants (PNSs) of labeled cell homogenates were
Fig. 2. Addition of the Fyn membrane-binding signal to the Gag N terminus does not alter the site of virus assembly. (A) Schematic representation of Gag mutants.
Positions of N-terminal myristate (m) and palmitate (palm) moieties are shown. (B) HeLa cells were transfected with either pNL4-3 derivatives encoding WT or Fyn
(10)fullMA Gag or a plasmid expressing FynGFP. Gag was detected by immunostaining using an anti-p17 monoclonal antibody and anti-mouse IgG conjugated with
AlexaFluor 488. Images were acquired by a Nikon TE2000 microscope equipped with a CCD camera and deconvolved with the Huygens software.
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gradients. Gag proteins in the top (membrane-bound) and bottom
(non-membrane-bound) fractions were recovered by immunopre-
cipitation with HIV immunoglobulin (HIV-Ig) and the efficiency
of Gag–membrane binding was compared between untreated and
cholesterol-depleted cells. Approximately half of the total Gag was
detected in membrane fractions in untreated cells whereas, in
cholesterol-depleted cells, only 25–30% of total Gag was
membrane-bound (Figs. 1A and B). Similar results were obtained
when pNL4-3/PR− was introduced into cells by transfection (see
below). In contrast, membrane binding of FynGFP was unaffected
(Figs. 1A and C) indicating that cholesterol depletion does not
globally disrupt cellular membrane. These results demonstrate that
Gag–membrane binding is facilitated by PM cholesterol.
The efficiency of higher-order Gag multimerization is reduced
by cholesterol depletion
As we reported recently, membrane-bound Gag undergoes
higher-order multimerization that masks Gag epitopes and
impairs immunoprecipitation of Pr55Gag (Ono et al., 2005). For
this reason, in the experiments described in Figs. 1A–C, Gag-
containing fractions were denatured prior to immunoprecipita-
tion so that higher-order Gag multimers were dissociated and
fully recognized by anti-Gag antibodies. By comparing the
efficiency of Gag immunoprecipitation from denatured and
non-denatured samples, we can assess the level of higher-order
Gag multimerization (Ono et al., 2005). Using this approach, we
examined the impact of cholesterol depletion on higher-order
Gag multimerization. In the untreated cultures, only 25% of
membrane-bound Gag was recovered without denaturationversus with denaturation (Fig. 1D), suggesting that a majority of
membrane-bound Gag is in higher-order multimers. In contrast,
in cultures treated with cholesterol-depleting agents, nearly half
of the total membrane-bound Gag was readily immunoprecipi-
tated without prior denaturation (Fig. 1D). These results
indicate that PM cholesterol enhances higher-order Gag multi-
merization in addition to Gag–membrane binding.
A heterologous membrane-binding signal reverses the impact
of cholesterol depletion on Gag–membrane binding and
higher-order multimerization
As described above, membrane binding of FynGFP, unlike that
of Gag, was insensitive to cholesterol depletion. We hypothesized
that Gag–membrane binding mediated by the native Gag N
terminus requires intact lipid rafts whereas membrane binding
mediated by the Fyn N terminus, which is myristylated and dually
palmitoylated, does not require raft structures. To analyze directly
the involvement of the Gag N-terminus in the sensitivity of Gag–
membrane binding to cholesterol depletion, we constructed a Gag
derivative in which the Fyn N-terminus is fused to the N-terminus
of Gag [Fig. 2A, Fyn(10)fullMA].We first examined whether Fyn
(10)fullMAGag forms virus particles at the plasmamembrane like
WT Gag. We transfected HeLa cells with either HIV-1 molecular
clones encoding WT or Fyn(10)fullMA Gag or the plasmid
encoding FynGFP (Fig. 2B). To detect Gag associated with
assembling particles, the anti-p17 monoclonal antibody was used
for immunostaining. As observed with WT Gag and FynGFP, a
majority of the Fyn(10)fullMA Gag signal localized to the PM,
indicating that Fyn(10)fullMA Gag, like WT Gag, forms virus
particles at the PM.
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cholesterol dependence of Gag binding to membrane, we then
transfected HeLa cells with pNL4-3/PR− or pNL4-3/Fyn(10)
fullMA/PR−. Cells were metabolically pulse-labeled for 5 min
and chased for 15 min, and PNSs were subjected to equilibrium
flotation centrifugation. To examine simultaneously the impact
of MβCD treatment on higher-order Gag multimerization,
immunoprecipitation of labeled Gag in membrane and non-
membrane fractions was performed with or without prior
denaturation (Fig. 3). In this series of experiments, ∼30% of
WT Gag was associated with membrane whereas ∼80% of Fyn
(10)fullMA Gag was in membrane fractions within the 15-min
chase period. As observed in Figs. 1A and B, partitioning of WT
Gag into membrane fractions was reduced approximately 50%
by cholesterol depletion (Fig. 3A). In contrast, membrane
binding of Fyn(10)fullMA Gag was insensitive to cholesterol
depletion. Interestingly, unlike WT Gag, higher-order multi-
merization of Fyn(10)fullMA Gag was also resistant to
cholesterol depletion (Fig. 3B). These results show that the
effect of cholesterol depletion on Gag–membrane binding and
higher-order Gag multimerization can be reversed by increasing
the ability of Gag to bind membrane.
The Fyn N-terminus largely reverses the impact of cholesterol
depletion on virus particle production
To examine whether the effects of cholesterol depletion can
be reversed by the Fyn membrane binding signal, we transfected
HeLa cells with molecular clones expressing either WT Gag or
Fyn(10)fullMA Gag and metabolically labeled with [35S]Met/
Cys following cholesterol depletion with MβCD. Labeled Gag
proteins were immunoprecipitated from cell and virus lysates
with HIV-Ig and virus release efficiency was determined by
measuring the amount of released, virion-associated p24
normalized for total labeled Gag (Fig. 3C). As we reported
previously (Ono and Freed, 2001), virus particle production
from cells expressing WT Gag was reduced approximately
fivefold by cholesterol-depleting agents. By comparison, virus
release efficiency from cells expressing Fyn(10)fullMA Gag
was significantly less sensitive to MβCD treatment. These
results indicate that the N terminus of Fyn confers upon Gag
resistance to cholesterol depletion. Similar results were obtained
when we examined the effect of MβCD on the release of a Gag
chimera containing the Fyn membrane targeting signal in the
context of a mutant Gag containing deletions in both MA and
NC. We observed that release of VLPs generated by this
construct, Fyn(10)ΔMAdelNC (Ono et al., 2004), was mini-
mally affected, with a reduction of only ∼10% relative to the
WT. These results support the conclusion that linking Gag to a
potent, heterologous membrane targeting signal reverses the
impact of cholesterol depletion on virus release.
Discussion
Depletion of cellular cholesterol, which is essential for the
integrity of lipid raft microdomains, markedly inhibits HIV-1
particle production. However, which step(s) in the virus particleassembly and release pathway requires membrane cholesterol
and/or lipid rafts was unknown. To address this question, in this
study we examined the impact of cholesterol depletion on each
step of virus particle production using microscopic and
biochemical methods. Immunofluorescence and EM experi-
ments suggest that cholesterol depletion has no major impact on
Gag localization to the plasma membrane, or on the pinching-
off of budding particles (unpublished data). In biochemical
experiments, however, we found that depletion of cellular
cholesterol markedly reduced the binding of Gag to membrane
(Fig. 1). Importantly, membrane binding of the lipid raft marker
FynGFP, as well as that of Fyn(10)fullMA Gag, was insensitive
to cholesterol depletion (Figs. 1 and 3) although, like WT Gag,
both FynGFP and Fyn(10)fullMA Gag associate with the PM
(Fig. 2). These results indicate that the decrease in Gag–
membrane binding is not due to a global disruption of cellular
membrane by cholesterol depletion. Together with the previous
reports supporting the notion that Gag associates with lipid rafts
(Ding et al., 2003; Feng et al., 2003; Guo et al., 2005; Halwani
et al., 2003; Holm et al., 2003; Jolly and Sattentau, 2005;
Lindwasser and Resh, 2001; Lindwasser and Resh, 2002;
Nguyen and Hildreth, 2000; Ono and Freed, 2001; Ono et al.,
2005; Pickl et al., 2001; Yang and Ratner, 2002), our data
suggest that membrane binding of Gag is enhanced by the
presence of cholesterol-enriched microdomains in the plasma
membrane.
In addition to Gag–membrane binding, higher-order Gag
multimerization was also reduced by cholesterol depletion (Fig.
1). Interestingly, upon addition of Fyn-derived sequences to the
Gag N-terminus, not only Gag–membrane binding but also
higher-order Gag multimerization was rendered insensitive to
cholesterol depletion (Fig. 3). It is possible that the high-affinity
membrane binding mediated by the Fyn N-terminus substan-
tially increased the number of Gag molecules present on the
membrane and thereby diminished the role of intact rafts in
promoting efficient Gag multimerization. In other words,
enhancement of Gag multimerization by rafts is observable
only when a limited number (i.e., the WT level) of Gag
molecules is present on the membrane. As a twofold decrease in
the efficiency of Gag–membrane binding results in a significant
inhibition of virus particle production (Ono and Freed, 1999),
the cumulative defects in Gag–membrane binding and higher-
order Gag multimerization likely account for the virus release
defects caused by cholesterol depletion. Indeed, the relative
efficiency of virus release after cholesterol depletion was largely
restored upon addition of the Fyn N-terminal sequence, which
reversed defects in both Gag membrane binding and multi-
merization (Fig. 3C). Infectivity of virus particles formed by
Fyn(10)fullMA Gag was reduced more than 50-fold (AW and
EF, unpublished observation).
How would PM cholesterol facilitate Gag–membrane
binding? It is possible that the observed effect of cholesterol
depletion on Gag–membrane binding is due to disruption of a
cholesterol-mediated function unrelated to rafts. In addition to
disruption of raft microdomains, cholesterol depletion has been
shown to inhibit clathrin-mediated endocytosis (Rodal et al.,
1999; Subtil et al., 1999). However, we did not observe any
Fig. 3. Defects in Gag membrane binding, higher-order Gag multimerization,
and VLP release in cholesterol-depleted cells are restored upon addition of the
Fyn membrane-binding signal to the Gag N terminus. HeLa cells were
transfected with pNL4-3/PR− or the pNL4-3/PR− derivative encoding Fyn(10)
fullMA Gag. Cells were treated (+) or not (−) with MβCD and membrane
binding (A) and epitope exposure (B) of Gag were analyzed as in Fig. 1. Data
from three independent experiments were quantified by phosphorimager
analysis and are shown as means±standard deviations. p values were
determined by the Student's t-test (*p<0.05). In (C), HeLa cells transfected
with pNL4-3 or its derivative encoding Fyn(10)fullMA Gag were treated (+) or
not (−) with MβCD and labeled metabolically with [35S]Met/Cys for 2 h.
Labeled Gag proteins in cell and virus lysates were immunoprecipitated and
quantified by phosphorimager analyses. Virus release efficiency was calculated
as described in Materials and Methods and normalized to untreated cultures. p
values were determined by the Student's t-test (***p<0.0001; ns, not
significant). The actual average virus release efficiency of untreated cultures
expressing WT Gag is 11% and that of Fyn(10)fullMA Gag is 33%.
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mediated endocytosis was blocked by expression of a
dominant-negative version of a regulatory protein (Ono et al.,
2004). Cholesterol depletion has also been reported to reduce
levels of the plasma membrane phospholipid, phosphatidylino-
sitol-(4,5)-bisphosphate [PI(4,5)P2] (Kwik et al., 2003). Since
PI(4,5)P2 depletion severely impairs virus production (Ono
et al., 2004), and Gag appears to interact directly with this
lipid (Saad et al., 2006; Shkriabai et al., 2006), it is possible
that cholesterol depletion might indirectly affect Gag–
membrane binding through PI(4,5)P2 reduction. However,
reductions in the levels of plasma membrane PI(4,5)P2
caused relocalization of Gag to late endosomes/MVBs (Ono
et al., 2004); this effect on Gag targeting was not observed
upon cholesterol depletion (unpublished data). Therefore,
these reportedly raft-independent cholesterol functions are
unlikely to be involved in the disruption of Gag–membrane
binding observed upon cholesterol depletion.
We postulate a model in which lipid rafts stabilize Gag–
membrane interaction by facilitating the exposure of the N-
terminal myristate moiety. A recent NMR analysis of
myristylated MA in solution showed that the exposed and
sequestered states of the myristate moiety are in equilibrium
(Tang et al., 2004). Importantly, Gag–Gag interaction substan-
tially shifted the equilibrium towards myristate exposure (Tang
et al., 2004). If rafts enhance Gag–Gag interactions, exposure of
the myristate moiety will likely be increased upon raft
association. Alternatively, raft binding may stabilize the
exposed conformation of the N-terminal myristyl chain. The
NMR study suggested that the exposure of myristate is coupled
with MA trimerization (Tang et al., 2004) and that, at least in
solution, MA trimerization is driven by interactions between
exposed myristyl groups (Tang et al., 2004). In the presence of
membrane lipids, hydrophobic interactions between the myr-
istate moiety and lipid acyl chains would likely replace the
interactions between myristates observed in solution (Tang et
al., 2004). Lipid rafts, which are enriched in saturated lipids, are
proposed to contain tightly packed liquid-ordered structures
(Brown and London, 2000; Simons and Toomre, 2000; Simons
and Vaz, 2004). The myristyl moiety attached to Gag may thus
form hydrophobic interactions with acyl chains of membrane
lipids more efficiently and thereby support more stable Gag–
membrane interaction in rafts than in non-ordered membrane
microdomains.
Although palmitoylation is well known to promote raft
association, membrane binding of Fyn(10)fullMA Gag was
unaffected by cholesterol depletion (Fig. 3). In this case,
probably due to the high affinity of the 16-carbon palmitate
moiety for membrane, the presence of liquid-ordered membrane
microdomains did not enhance further the membrane binding of
Fyn(10)fullMA Gag. There are, however, two other reported
cases in which rafts are not required for HIV-1 Gag–membrane
binding (Guo et al., 2005; Lindwasser and Resh, 2002). In one
study, the N-terminal myristate moiety was substituted with a
kinked acyl chain (Lindwasser and Resh, 2002). In the other
study, Gag–membrane binding was artificially enhanced by an
MA mutation (Guo et al., 2005). According to the model
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not have been regulated by the equilibrium between the
exposure and sequestration of the myristate moiety, and as a
result, membrane binding became raft-independent. It would be
interesting to analyze effects of cholesterol depletion on
membrane binding of retroviral Gag proteins that naturally do
not require myristylation for Gag–membrane interaction (e.g.,
Gag proteins of equine infectious anemia virus and Rous
sarcoma virus). In this regard, it is noteworthy that Rous
sarcoma virus MA showed no preference for raft-like
membranes in in vitro liposome binding assays (Dalton et al.,
2005).
In summary, the results reported here demonstrate that
plasma membrane cholesterol facilitates virus particle produc-
tion by promoting Gag–membrane binding and higher-order
Gag multimerization presumably as a component of liquid-
ordered membrane microdomains. To our knowledge, this is
the first report showing that membrane cholesterol facilitates
the interaction of a myristylated protein with the cytoplasmic
leaflet of the plasma membrane. An increasing number of
enveloped and non-enveloped viruses are proposed to
associate with lipid rafts during assembly (Briggs et al.,
2003; Ono and Freed, 2005; Suomalainen, 2002). Analysis of
the relationships between cholesterol-enriched lipid rafts and
particle production mediated by these viruses will likely
elucidate common aspects of membrane microdomains that
are exploited by diverse viruses.
Materials and methods
Plasmids
Molecular clones encoding Gag derivatives, pNL4-3/Fyn
(10)fullMA and pNL4-3/Fyn(10)ΔMA/delNC (Ono et al.,
2004), or an inactive PR [pNL4-3/PR−, (Huang et al., 1995)]
were described previously. A PR− version of pNL4-3/Fyn(10)
fullMA [pNL4-3/Fyn(10)fullMA/PR−] was constructed by
introducing the SphI-to-EcoRI fragment (pNL4-3 nt 1443–
5743) from pNL4-3/PR− into pNL4-3/Fyn(10)fullMA. Con-
struction of pCMVNLGagPolRRE using pCMVGagPolRRE [a
kind gift from D. Rekosh, University of Virginia (Srinivasaku-
mar et al., 1997)] was described previously (Ono and Freed,
2001). The VSV-G expression vector pHCMV-G (Yee et al.,
1994) was generously provided by J. Burns (University of
California, San Diego). An expression plasmid encoding
FynGFP (van't Hof and Resh, 1997) was kindly provided by
M. Resh (Memorial Sloan-Kettering Cancer Center).
Cells, transfections, and infections
HeLa cells were cultured as previously described (Freed and
Martin, 1994). Gag was expressed either by transfecting cells
with molecular clones or by infecting with high-titer vector
virus stocks. Transfection of HeLa cells was performed by the
calcium phosphate method as previously described (Freed and
Martin, 1994) or by using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's instructions. Infection of HeLacells with virus stocks pseudotyped with VSV-G was performed
as described previously (Ono et al., 2005). VSV-G-pseudotyped
virus stocks were prepared by transfecting HeLa cells with
pCMVNLGagPolRRE, pHCMV-G, and the molecular clone
pNL4-3/PR−.
Cholesterol depletion, metabolic labeling, and
immunoprecipitation
Depletion of cholesterol and metabolic labeling were
performed as described previously (Ono and Freed, 2001).
Briefly, HeLa cells were cultured in Met−/Cys− RPMI-1640
supplemented with 2% cholesterol-depleted serum (CDS) in
the presence of 10 mM MβCD for 30 min. Subsequently,
cells were metabolically labeled with [35S]Met/Cys in Met−/
Cys− RPMI-1640 supplemented with 2% CDS for 2 h for
the analyses of virus release efficiency. Preparation of cell
lysates, pelleting of virions in the ultracentrifuge, and
immunoprecipitation of cell- and virion-associated proteins
with HIV-Ig (obtained from the NIH AIDS Research and
Reference Reagent Program) was detailed previously (Freed
and Martin, 1994). Quantification of immunoprecipitated
proteins was performed by phosphorimager analysis. Virus
release efficiency was calculated as the amount of virion-
associated Gag as a fraction of total (cell plus virion) Gag
synthesized during a 2-h labeling period. For membrane
binding analyses, MβCD-treated cells were pulse labeled
with [35S]Met/Cys in Met−/Cys− RPMI-1640 supplemented
with 2% CDS for 5 min and chased in DMEM containing
5% CDS for 15 min. Alternatively, cells were cultured for
2 days in DMEM containing 5% CDS in the presence of
2 μM simvastatin and 500 μM mevalonate. After starving in
RPMI-Met−/Cys− medium containing 2 μM simvastatin and
500 μM mevalonate for 30 min, cells were labeled in the
same medium with [35S]Met/Cys for 5 min followed by a
15-min chase period.
Membrane binding analyses and denaturation of Gag
Analyses of Gag–membrane binding were performed as
previously described (Ono et al., 2000a; Ono and Freed, 1999;
Ono and Freed, 2001; Ono et al., 2005). Denaturation of Gag
was performed as described previously (Ono et al., 2005).
Immunofluorescence microscopy
Fixation, permeabilization, and immunostaining of trans-
fected HeLa cells were performed as previously described (Ono
et al., 2004; Ono and Freed, 2004; Ono et al., 2000b). Gag
proteins were detected using monoclonal anti-p17 antibody or a
mixture of monoclonal anti-p17 and anti-p24 antibodies
(Advanced Biotechnologies). After staining, cells were
mounted with Fluoromount G (Electron Microscopy Sciences,
Fort Washington, PA) and examined with a Nikon TE2000
microscope equipped with CoolSnap ES CCD camera (Photo-
metrics). Images were deconvolved using Huygens software
(Scientific Volume Imaging).
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